



UK HCV COHORTS

Andy Ustianowski

Chair: British Viral Hepatitis Group

Consultant & Research Lead, NW Infectious Diseases Unit,
Manchester, UK

EUROPEAN HIV HEPATITIS CO-INFECTION (EHHC)
CONFERENCE



Dr Andrew Ustianowski

North Manchester General Hospital, UK

| COMPETING INTEREST OF FINANCIAL VALUE \geq £1,000: | |
|--|--|
| Speaker Name | Statement |
| Andrew Ustianowski | Acts in a consultancy capacity and as a speaker at company-sponsored events for Abbvie, BMS, Gilead, Janssen, MSD, ViiV. |
| Date | 7 th December 2015 |



What do we have?

- The English SOF Early Access Programme Cohort
- Not much else...
but lots of potential....



English Early Access Program (EAP)



- 12 weeks sofosbuvir & ledipasvir or daclatasvir
+/- RBV
 - Clinicians were free to select the regime
- Inclusion Criteria:
 - Decompensated cirrhosis with previous or present ascites/variceal bleed/encephalopathy
 - CTP score ≥ 7
 - Non-hepatic manifestation likely to lead to irreversible damage in 12 months and intolerant to or failed Peg INF/RBV
 - Exceptional circumstances by panel review

Physician Treatment Selection

| Regime | G1 | G3 | Others | Total |
|-----------------------------|---------------|---------------|-------------|---------------|
| SOF/LDV/RBV N (%) | 164 (35.1) | 61 (13.1) | 27 (5.8) | 252 (54.0) |
| SOF/DCV/RBV N (%) | 45 (9.6) | 114 (24.4) | 13 (2.8) | 172 (36.8) |
| Without RBV N (%) | 26 (5.6) | 14 (3.0) | 3 (0.6) | 43 (9.2) |
| Total N (%) | 235 (50.3) | 189 (40.5) | 43 (9.2) | 467 |

SOF=sofosbuvir; LDV=ledipasvir; DCV= daclastavir; RBV=ribavirin

Adapted from Foster *et al.* oral presentation at EASL 2015 Vienna 22-26 April 2015

Baseline Characteristics

| | Total | G1 | G3 | Others |
|---|-----------------|-----------------|----------------|---------------|
| N (%) | 467 | 235 (50.3%) | 189 (40.5%) | 43 (9.2%) |
| Mean Age, years (Range) | 55.6 (29-81) | 56.1 (29-76) | 54 (36-75) | 59 (36-81) |
| Male (%) | 337 (72.2%) | 174 (74.0%) | 131 (69.3%) | 32 (74.4%) |
| Treatment experienced (%) | 220 (47.1%) | 107 (45.5%) | 88 (46.6%) | 25 (58.1%) |
| Liver transplanted (%) | 47 (10.1%) | 27 (11.5%) | 15 (7.9%) | 5 (11.6%) |
| White (%) | 345 (73.9%) | 193 (82.1%) | 128 (67.7%) | 24 (55.8%) |
| BMI – mean, kg/m² | 28.6 | 28.5 | 28.3 | 29.7 |
| HIV positive (%) | 23 (5.7%) | 17 (4.2%) | 6 (1.5%) | 0 (0%) |
| Mean HCV RNA, log₁₀ IU/mL | 6 | 6 | 5.9 | 5.9 |

BMI=Body Mass Index

Foster *et al.* oral presentation at EASL 2015 Vienna 22-26 April 2015


Baseline Characteristics

| | Total N = 467 | G1 N = 235 | G3 N = 189 | Others N = 43 |
|--|------------------|----------------|----------------|------------------|
| Decompensated cirrhosis (Past or present %) | 441 (94.4%) | 223 (94.9%) | 179 (94.7%) | 39 (90.7%) |
| CP-B (%) | 309 (66.2%) | 161 (68.5%) | 121 (64.0%) | 27 (62.8%) |
| CP-C (%) | 46 (9.9%) | 19 (8.1%) | 24 (12.7%) | 3 (7.0%) |
| MELD mean (range) | 11.9 (6-36) | 11.3 (6-24) | 12.6 (6-36) | 11.9 (6-22) |
| Active ascites (%) | 178 (38.1%) | 97 (41.3%) | 67 (35.4%) | 14 (32.6%) |
| Previous variceal bleed (%) | 127 (27.2%) | 61 (26.0%) | 55 (29.1%) | 11 (25.6%) |
| Active encephalopathy (%) | 80 (17.1%) | 41 (17.4%) | 34 (18.0%) | 5 (11.6%) |

CP = Childs Pugh; MELD=Model for End-Stage Liver Disease

Foster *et al.* oral presentation at EASL 2015 Vienna 22-26 April 2015

SVR12 by Genotype and Regime



SOF=sofosbuvir; LDV=ledipasvir; DCV= daclastavir; RBV=ribavirin
Foster *et al.* oral presentation at EASL 2015 Vienna 22-26 April 2015

SVR12 defined as HCV RNA at 12 weeks post-treatment < 30 IU/ml

Serious Adverse Events (by follow up week 4)

| | Number of events (% of total SAEs) | Number of patients (% of total population) |
|---|---------------------------------------|---|
| Total SAEs | 175 | 119 (25.5%) |
| Likely related to liver disease and/or HCV therapy | 138 (78.9%) | 100 (21.4%) |
| Likely unrelated to liver disease and/or HCV therapy | 37 (21.1%) | 37 (7.9%) |
| Ascites | 55 (31.4%) | 38 (8.1%) |
| Hepatic encephalopathy | 28 (16%) | 23 (4.9%) |
| Variceal bleed | 6 (3.4%) | 6 (1.3%) |
| Infection | 26 (14.9%) | 23 (4.9%) |
| Liver transplantation | | 16 (3.4%) |
| New HCC | | 7 (1.5%) |
| Discontinuation of DAAs | | 42 (9%) |
| Deaths | | 14 (3.0%) |

SAE=Serious adverse events; HCC=Hepatocellular carcinoma; DAA=Directly acting antivirals

Foster *et al.* oral presentation at EASL 2015 Vienna 22-26 April 2015

NHS England SOF Early Access Scheme

- Original data presented
 - N=467
- Dataset now 840
 - And being prepared for publication

So what else?

- HCV Research UK
- English ODN Networks
- Others?

HCV Research UK



- Inclusion criteria:
 - HCV R UK registered site
 - Informed consent
- Biobank samples
- N= 10,825 patients
- Requests for data +/- samples from the wider academic community
- But not a 'cohort' as such

England: Operational Delivery Networks

HEP C ODNs AND CLINICAL LEADS



North

1, North East & Cumbria
The Hancock Upper Tyne Hospitals
NHS Foundation Trust
Dr Stuart McPherson

2, Greater Manchester
& Eastern Cheshire
Pennine Acute Hospitals NHS Trust
& Central Manchester University
Hospitals NHS Foundation Trust
Dr Andrew Lickrowitz

3, Cheshire & Merseyside
Royal Liverpool & Broad Green
University Hospital NHS Trust
Dr Paul Richardson
Professor Anna Maria Girelli

4, South Yorkshire
Sheffield Teaching Hospitals NHS
Foundation Trust
Dr Ben Stone

5, Humberside and
North Yorkshire
Hull & East Yorkshire NHS Trust
Dr Peter Allen

6, West Yorkshire
Leeds Teaching Hospitals
Dr Mark A Alderson

7, Lancashire and South
Cumbria (in development)

Midlands & East

8, Leicester
University Hospitals of Leicester
Dr Martin Whittle

9, Birmingham
University Hospitals Birmingham
NHS Foundation Trust
Professor David Mulline

10, Nottingham
Nottingham University
Hospitals NHS Trust
Dr Stephen Sykes

11, Eastern Hepatitis Network
Cambridge University Hospital NHS
Foundation Trust
Dr William Galton

London North West

12, West London
Imperial College Healthcare Trust
Prof Mark Thursz

North Central London

13, North Central London
Viral Hepatitis Network
Royal Free London NHS
Foundation Trust
Prof William Rosenberg

London North East

14, Barts
Barts Health (Royal London Site)
Prof Graham Fowler

London South

15, South Thames Hepatitis
Network (STHePNet) Kings
& St George's
Kings College Hospital NHS
Foundation Trust and St George's
University Hospital NHS
Foundation Trust
Dr Kesh Aggarwal
Dr Sam Arora

South

16, Surrey Hepatitis Services
Royal Surrey County Hospital NHS FT
Dr Michelle Gallagher

17, Sussex Hepatology
Network
Brighton & Sussex University
Hospitals - Royal Sussex County
Hospital (RSCG)
Dr Jeremy Tibble

18, Oxford University
Hospitals NHS Trust
Oxford
Dr Jane Collins

19, Wessex Hep C ODN
University Hospital Southampton
NHS Foundation Trust
Dr Mark Wajsbort

20, Bristol and Severn
Hep C ODN
University Hospitals Bristol NHS
Foundation Trust
Dr Fiona Gordon

21, South West Peninsula
Hepatitis C ODN
Plymouth Hospitals NHS Trust
Professor Matthew Cramp

22, Kent Network via Kings
Kings College Hospital NHS
Foundation Trust
Dr Kesh Aggarwal



Presently getting through
5000 cirrhotics.....

Estimates of England HCV epidemiology 2016

- Undiagnosed: 67,000
- Diagnosed:
 - F0-2: 81,000
 - F3: 13,000
 - F4: 3,500
 - ESLD: 1,000
- G1: 47%
- G3: 44%
- PWID: approx. 50% infected
- HIV co-infected:
 - Incidence declining in MSM – 2.3/1000 person years

Others...

- Scotland:
 - Data not yet collated...
 - Approx 1,500 patients treated in 2015-16
 - Mainly DAA-only therapy

